These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 35310225)

  • 1. Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.
    Sekula AD; Downey L; Puspanathan P
    Front Psychol; 2022; 13():813746. PubMed ID: 35310225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
    Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.
    Fonseka LN; Woo BK
    World J Psychiatry; 2023 May; 13(5):182-190. PubMed ID: 37303932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelics and virtual reality: parallels and applications.
    Aday JS; Davoli CC; Bloesch EK
    Ther Adv Psychopharmacol; 2020; 10():2045125320948356. PubMed ID: 32922734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
    Schmid Y; Gasser P; Oehen P; Liechti ME
    J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
    Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D
    Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 11. Psychedelics in the treatment of unipolar and bipolar depression.
    Bosch OG; Halm S; Seifritz E
    Int J Bipolar Disord; 2022 Jul; 10(1):18. PubMed ID: 35788817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
    Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
    J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.
    Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR
    Front Psychol; 2017; 8():1238. PubMed ID: 28790944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.
    Gründer G; Jungaberle H
    Pharmacopsychiatry; 2021 Jul; 54(4):191-199. PubMed ID: 33979868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic-Assisted Group Therapy: A Systematic Review.
    Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
    J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenomenology, Structure, and Dynamic of Psychedelic States.
    Preller KH; Vollenweider FX
    Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.